Seeking Alpha

Buy the recent weakness in Endo Pharmaceuticals (ENDP +0.5%) sparked by yesterday's FDA's denial...

Buy the recent weakness in Endo Pharmaceuticals (ENDP +0.5%) sparked by yesterday's FDA's denial of ViroPharma's Vancocin citizen petition, Cantor Fitzgerald says. The firm notes heightened investor anxiety around approval of ENDP's generic Liboderm amid the VPHM news, but it believes "Vancocin is not a good proxy for Liboderm." (also)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector